Pramlintide

Treatments for type 1 diabetes must be tailored to the heterogeneity of disease physiology among patients, moving beyond population-based HbA1c measures to individualized glycemic time in targets, according to a speaker.

ADO09, a co-formulation of pramlintide and insulin A21G, was associated with better glucose levels, improved time in range and more weight loss among people with type 1 diabetes compared with insulin aspart, according to a presenter.